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Abstract
When evaluating medical tests or biomarkers for disease classification, the area under the
receiver-operating characteristic (ROC) curve is a widely used performance metric that does not
require us to commit to a specific decision threshold. For the same type of evaluations, a different
metric known as the average precision (AP) is used much more widely in the information retrieval
literature. We study both metrics in some depths in order to elucidate their difference and
relationship. More specifically, we explain mathematically why the AP may be more appropriate
if the earlier part of the ROC curve is of interest. We also address practical matters, deriving
an expression for the asymptotic variance of the AP, as well as providing real-world examples
concerning the evaluation of protein biomarkers for prostate cancer and the assessment of digital
versus film mammography for breast cancer screening.
Key Words: AUC; average precision; prevalence; ROC curve; screening test.
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1 Introduction
There are many different metrics for evaluating diagnostic and screening tests in medical sciences;
the book by Pepe (2003) is an authoritative reference in this field. Commonly used metrics include
sensitivity, specificity, positive and negative predictive values, positive and negative diagnostic
likelihood ratios, among many others. All the aforementioned metrics require the underlying test
to make a binary decision, that is, whether the patient being tested has a certain disease or not.
Making such a binary decision usually requires a decision threshold, as the underlying test often
gives continuous measurements, such as the serum concentration of a metabolite, or the size and
density of a mass seen from a medical image. So, for example, the concentration of serum bilirubin
has to exceed a certain level for the test to flag the patient as being likely to have liver dysfunction.
Changing the decision threshold always will affect both the sensitivity and the specificity of the
test simultaneously — in particular, raising one while reducing the other.
The receiver operating characteristic (ROC) curve traces the tradeoff between sensitivity and
specificity as the decision threshold varies. Looking at the entire ROC curve is especially useful
when we are not ready to commit to a particular decision threshold. Nonetheless, sometimes we still
prefer to have a single, numeric performance metric, for example, when we are evaluating hundreds
of potential biomarkers — comparing hundreds of ROC curves is simply not practical or efficient.
The Area Under the ROC Curve (AUC) is a much widely used choice in this context — tests with
larger AUC values are considered more powerful. Thus, researchers may pre-screen hundreds of
the potential biomarkers using the AUC, and then compare just a handful of top biomarkers using
the entire ROC curve. Again, we refer the readers to the book by Pepe (2003) and its extensive
bibliography for more detailed discussions of these issues.
Despite its popularity, the AUC is not perfect. We have encountered two common criticisms
about the AUC:
(C1) Two “qualitatively different” tests can quite often turn out to have roughly the same AUC
values (e.g., Hand 2009; Alemayehu and Zou 2012).
(C2) The ROC curve is not equally relevant everywhere; in practice, the initial part of the curve
is much more important (McClish 1989; Zweig and Campbell 1993; Baker and Pinsky 2001;
Dodd and Pepe 2003; Alemayehu and Zou 2012).
A natural response to criticism (C2) is the notion of the “partial AUC” — the area under the ROC
curve up to a certain cutoff value (see, e.g., McClish 1989; Thompson and Zucchini 1989; Jiang
et al. 1996). We find the partial AUC somewhat unsatisfying because it depends on a subjective
cutoff value, which must be supplied a prior. And, to date, we have known of few effective responses
to criticism (C1).
The information retrieval (IR) community faces a similar problem. Mathematically, the fol-
lowing two questions are equivalent:
1. How effective can a retrieval algorithm tell if a document is relevant or not?
2. How effective can a diagnostic (or screening) test tell if a patient is diseased or not?
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However, to answer their question, the IR community tends to rely much more heavily (though not
exclusively) on another performance metric known as the average precision (AP) — see, e.g., Peng
et al. (2003) and references therein. Like the AUC, the AP is another single, numeric performance
metric that does not require us to commit to a decision threshold priori to the analysis. The
relationship between these two threshold-free evaluation metrics seems poorly understood, though,
if at all. We studied both metrics out of curiosity. After doing so, we found that, to some extent,
the AP actually seems to address both criticisms (C1) and (C2) of the AUC.
We proceed as follows. In Section 2, we define various quantities of interest using a common
set of notations. In Section 3, we develop some theoretical insights. More specifically, we introduce
two notions, which we call stamina and momentum, and show that, for the AUC, stamina and
momentum are equally important, whereas for the AP, momentum is more important. In Section 4,
we address some practical issues. In particular, we show how the AP is calculated in practice, and
derive its asymptotic variance. In Section 5, we provide two examples. In Section 6, we discuss
various practical implications of our result. In particular, we discuss when the AP may be considered
a more attractive performance metric than the AUC.
2 Definitions
Suppose there are a total of n subjects, some (n1) of which are diseased (class 1) and the rest
(n0 = n − n1) of which are not (class 0). For every subject i, a diagnostic (or screening) test
produces a score, xi, which we can use to rank (or order) the subjects — e.g., a high score (large
xi) means the subject is more likely to be diseased, and vice versa. In this section, we define
various concepts associated with evaluating the effectiveness of such a test. The ultimate objective,
of course, is to formally define the AUC and the AP so that they can be studied together. In order
to do so, it is convenient to start with the so-called hit curve.
2.1 The hit curve
Let i denote the ordered subject index, that is, x1 ≥ x2 ≥ ... ≥ xn. If we threshold the scores at
xk, declaring all those with scores ≥ xk to be class-1 and all those with scores < xk to be class-0,
we will have a confusion matrix as displayed in Table 1, where d(k) is the number of subjects with
scores ≥ xk, and ~(k) is the number of subjects truly belonging to class-1 out of those declared to
be class-1. Clearly, ~(k) is a discrete function, defined only on the set of nonnegative integers up
to n.
In the literature, it is also common to represent the confusion matrix (Table 1) in terms of
proportions rather than in terms of counts. This is given explicitly in Table 2, where
t ≡ d(k)
n
, pi ≡ n1
n
, and h(t) ≡ ~(k)
n
. (1)
When n is relatively large, it is convenient to think of the function h(t), defined on the interval [0, 1],
as a continuous object. In fact, we will further assume that it is differentiable almost everywhere.
This allows us to use the language of calculus — i.e., differentiation and integration — to discuss
various concepts. The collection of points, {(t, h(t)), t ∈ [0, 1]}, traces out a so-called hit curve. For
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Table 1: The confusion matrix based on counts.
Declared Class-1 Declared Class-0 Total
Class-1 ~(k) n1 − ~(k) n1
Class-0 d(k)− ~(k) [n− d(k)]− [n1 − ~(k)] n− n1
Total d(k) n− d(k) n
Table 2: The confusion matrix based on proportions.
Declared Class-1 Declared Class-0 Total
Class-1 h(t) pi − h(t) pi
Class-0 t− h(t) (1− t)− [pi − h(t)] 1− pi
Total t 1− t 1
simplicity, we will refer to h(t) itself as the hit curve as well. Like the ROC curve, the hit curve
also is a signature of the underlying test’s effectiveness. Proposition 1 below lists a few properties
of the hit curve that will be useful later; proofs are given in Appendix A.
Proposition 1 Let h(t) be a hit curve (see Table 2), assumed to be continuous and differentiable
almost everywhere. Then,
(a) h(0) = 0 and h(1) = pi;
(b) 0 ≤ h′(t) ≤ 1, for all t;
(c)
∫
h(t)dh(t) = pi2/2.
Remark In what follows, we will not distinguish between ~ and h. Whenever we write h(k), we
will be referring to the quantity defined in Table 1 and thinking of it as a discrete function on the
set {0, 1, 2, ..., n}. Whenever we write h(t), we will be referring to the quantity defined in Table 2
and thinking of it as a continuous function on [0, 1], with h(t) = h(k)/n.
2.2 The AUC
Suppose we threshold the scores at xk, a level such that t × 100% of the subjects are declared to
be class-1. The quantities
TPF(t) =
h(t)
pi
(
or TPF(k) =
h(k)
n1
)
and
FPF(t) =
t− h(t)
1− pi
(
or FPF(k) =
d(k)− h(k)
n− n1
)
are called the true positive fraction (TPF) and the false positive fraction (FPF), respectively —
refer to Tables 1–2. The ROC curve refers to the collection of points, {(FPF(t),TPF(t)), t ∈ [0, 1]}.
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The AUC is simply its area underneath, defined as
AUC ≡
∫
TPF(t)d[FPF(t)]. (2)
Using the definitions of TPF(t) and FPF(t) above, it is straight-forward to see that
AUC =
∫
h(t)
pi
d
[
t− h(t)
1− pi
]
=
1
pi(1− pi)
∫
h(t) (dt− dh(t))
=
1
pi(1− pi)
[∫
h(t)dt−
∫
h(t)dh(t)
]
=
1
pi(1− pi)
[∫
h(t)dt− pi
2
2
]
, (3)
where the final step is due to Proposition 1(c).
2.3 The AP
Instead of the TPF and the FPF, the IR community often speaks of the recall and the precision.
Again, suppose we threshold the scores at xk, a level such that t×100% of the subjects are declared
to be class-1. Then,
Recall(t) =
h(t)
pi
(
or Recall(k) =
h(k)
n1
)
,
which is the same as the TPF, and
Precision(t) =
h(t)
t
(
or Precision(k) =
h(k)
d(k)
)
.
The average precision (AP) is defined as (e.g., Zhu 2004)
AP ≡
∫
Precision(t)d[Recall(t)], (4)
which can be thought of as the area under the precision versus recall curve. Using the definitions
of Recall(t) and Precision(t) above, it is straight-forward to see that
AP =
∫
h(t)
t
× dh(t)
pi
=
1
pi
∫
h(t)
t
dh(t). (5)
2.4 Examples
For those not familiar with either of these concepts, they are often abstract and confusing enough
at first sight that a few examples are warranted. For those already comfortable with the ideas, this
section can be skipped.
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2.4.1 A random test
If a diagnostic (or screening) test is random, then h(t) = pit. That is, the true positive rate stays
constant at pi, the overall proportion of class-1 subjects. By Eq. (3), we have
AUC(Random) =
1
pi(1− pi)
[∫
pitdt− pi
2
2
]
= 1/2.
By Eq. (5), we have
AP(Random) =
1
pi
∫
pit
t
pidt = pi.
2.4.2 A perfect test
If a diagnostic (or screening) test is perfect, then
h(t) =
{
t, t ≤ pi;
pi, t > pi.
That is, the true positive rate is 100% until all class-1 subjects have been identified, after which
the true positive rate necessarily stays at zero. By Eq. (3), we have
AUC(Perfect) =
1
pi(1− pi)
[∫ pi
0
tdt+
∫ 1
pi
pidt− pi
2
2
]
= 1.
By Eq. (5), we have
AP(Perfect) =
1
pi
[∫ pi
0
t
t
× 1× dt+
∫ 1
pi
pi
t
× 0× dt
]
= 1.
2.5 Remarks
Notice that both the AUC and the AP, as we have defined them, are random variables, a point that
will become even clearer later in Section 4. Furthermore, according to Eqs. (3) and (5), both the
AUC and the AP are functionals of the hit curve h(t), a point that we will sometimes emphasize
by writing AUC(h) and AP(h).
3 Theory
In this section, we use a simple, parametric, quasi-concave model for the hit curve to gain some
important insight about the AUC and the AP.
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3.1 The quasi-concave model
Consider a quasi-concave hit curve (Figure 1), parameterized as follows:
h(t) =

βt, t ∈ [0, α];
pi − αβ
1− α (t− α) + αβ, t ∈ (α, 1].
(6)
There are two parameters: β ∈ [pi, 1] is the initial true positive rate of the underlying test, and
α ∈ [0, pi/β] is the change point at which the test’s true positive rate drops. The requirement
β ≥ pi ensures that the model is describing a test that is as least as good as random; worse-than-
random procedures are not interesting and practically irrelevant. The requirement β ≤ 1 is due to
Proposition 1(b). And, finally, the requirement α ≤ pi/β is because, with a true positive rate of β,
all class-1 subjects will have been identified by t = pi/β, leaving no more for t > pi/β.
3.2 Momentum and stamina
Despite its overwhelming simplicity, there are good reasons why the quasi-concave model (6) is
useful.
First, hit curves are typically concave, reflecting the fact that the true positive rate typically
drops as the scores decrease — that is, higher-ranked subjects are more likely than lower-ranked
ones to belong to class-1. Eq. (6) is arguably the simplest approximation possible to any concave
function. When β > pi, it is easy to see that the slope of the second segment, (pi − αβ)/(1− α), is
smaller than that of the first segment, β, which is why we use the name “quasi-concave”. This idea
of using a quasi-concave function to approximate a concave function is inspired by Laibson (1997),
who used “quasi-hyperbolic” discount functions to study time-inconsistent intertemporal choices in
behavioral economics.
Second, the two parameters, α and β, each capture an essential feature of the underlying
diagnostic (or screening) test:
α: As the change point at which the true positive rate drops, this parameter measures the
stamina of the test — how long can the initial, relatively high true positive rate “last”?
β: As the initial true positive rate, this parameter measure the momentum of the test — per-
forming at its best level, how fast can the test identify the subjects that it is supposed to
identify?
3.3 Momentum-stamina trade-off
For a quasi-concave hit curve, h(t), given by Eq. (6), it is easy to see that∫
h(t)dt =
βα2
2
+
(pi + βα)(1− α)
2
=
pi + βα− piα
2
=
pi + (β − pi)α
2
. (7)
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h(t)
t
α2 α1
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α
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α
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pi
h1(t)
h2(t)
Figure 1: Two quasi-concave hit curves, h1(t) and h2(t), parameterized respectively by (α1, β1)
and (α2, β2). In this illustration, the parameters α1, α2, β1, β2 are configured so that AUC(h1) =
AUC(h2) — see Theorem 1. But since β2 > β1, Theorem 2 implies that AP(h2) > AP(h1). In
practice, the initial part of the hit curve is often more relevant, which makes the AP a more useful
evaluation metric.
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Then, by Eq. (3),
AUC =
1
2pi(1− pi)
[
pi + (β − pi)α− pi2]
=
1
2pi(1− pi) [(β − pi)α] +
1
2
, (8)
which immediately implies Theorem 1 below.
Theorem 1 If two hit curves, h1(t) and h2(t), both belong to the quasi-concave family (6), and
are parameterized respectively by (α1, β1) and (α2, β2), then AUC(h1) = AUC(h2) if and only if
(β1 − pi)α1 = (β2 − pi)α2.  (9)
Theorem 1 explains that two diagnostic (or screening) tests h1 and h2 can have the same AUC
for different reasons. The trivial case is when both α1 = α2 and β1 = β2; this is when h1 and h2
are truly identical — same stamina and same momentum. However, if β1 < β2, then Theorem 1
implies that we must necessarily have α1 > α2, and vice versa. That is, on the AUC-scale, mediocre
momentum can be compensated by greater stamina, and vice versa. This provides a mathematically
explicit explanation for the reason behind criticism (C1), namely why two qualitatively different
tests can end up having similar AUC values.
3.4 AP versus AUC
What about the AP? If h(t) is a quasi-concave hit curve given by Eq. (6), then
dh(t) =

βdt, t ∈ [0, α];
pi − αβ
1− α dt, t ∈ (α, 1].
So,
AP =
1
pi
∫
h(t)
t
dh(t)
=
1
pi
∫ α
0
β2dt+
∫ 1
α
(
pi − αβ
1− α
)2
+
(
pi−αβ
1−α
)
αβ −
(
pi−αβ
1−α
)2
α
t
dt

=
1
pi
[
β2α+
(pi − αβ)2
1− α −
(
pi − αβ
1− α
)
(β − pi)α
1− α logα
]
.
Using the Taylor approximation that log(α) ≈ α− 1, the expression above can be simplified to
AP ≈ β
2α
pi
+ pi − αβ = β
pi
[(β − pi)α] + pi. (10)
Recall from Section 2.4 that AP(Random) = pi, AP(Perfect) = 1, AUC(Random) = 1/2, and
AUC(Perfect) = 1. We can rescale the AP and the AUC to both lie between 0 and 1:
A˜P ≡ AP− pi
1− pi (11)
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and
A˜UC ≡ AUC− 1/2
1− 1/2 = 2AUC− 1. (12)
Then,
A˜UC =
1
pi(1− pi) × [(β − pi)α]
by Eq. (8) and Eq. (12), while
A˜P ≈ 1
pi(1− pi) × β × [(β − pi)α]
by Eq. (10) and Eq. (11). These results establish Theorem 2 below.
Theorem 2 If a hit curve, h(t), belongs to the quasi-concave family (6), then
A˜P(h) ≈ β × A˜UC(h).  (13)
Theorem 2 suggests that, if two diagnostic (or screening) tests have the same AUC, then the AP
will “reward extra points” to the one with the larger momentum (larger β). Since momentum is
the initial true positive rate, this means the AP places more emphasis on the initial part of the
ROC curve. Hence, the AP can be seen as being based upon the AUC but having incorporated a
self-correcting factor in response to criticism (C2).
3.5 A simple simulation
The theoretical insights derived in the previous sections are based on using a quasi-concave model
for the hit curve. Here, we report a simple simulation study to investigate the applicability of
Theorem 2 to general hit curves, i.e., those outside the quasi-concave family, Eq. (6).
In the literature (see, e.g., Pepe 2003), it is customary to simulate diagnostic/screening tests
in the following way: Without loss of generality, scores given by the test to subjects in class-0
are simulated from f0(x) ∼ N(0, 1), and those given to subjects from class-1 are simulated from
f1(x) ∼ N(∆, 1) for some ∆ > 0. How well the scores rank the subjects (in terms of the AP and/or
the AUC) is then studied. The parameter, ∆, controls the strength of the simulated test — a large
∆ means the test tends to give much higher scores to subjects in class-1 than to those in class-0; it
is thus a more powerful test.
Given (n, pi,∆), we first generated npi scores from N(∆, 1,) and n(1 − pi) scores from N(0, 1).
Using these scores, we plotted the resulting hit curve, h(t), as well as computed AP(h) and AUC(h).
Then, we computed
β̂ =
A˜P(h)
A˜UC(h)
=
(AP(h)− pi)/(1− pi)
2AUC(h)− 1 , (14)
and plotted the line f(t) = β̂t on top of h(t). This procedure was easily repeated for many
combinations of (n, pi,∆).
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Fixing n = 500, Figure 2 shows four representative scenarios, generated by all combinations of
pi = 0.1 (low prevalence) or pi = 0.5 (high prevalence), and ∆ = 0.5 (weak test) or ∆ = 2 (strong
test). Our results, including those not shown in Figure 2, suggest that β̂, as given by equation (14),
is a good approximation of the initial true positive rate. This, in turn, verifies that the approximate
relationship (13) established by Theorem 2 is still useful even if the hit curve h(t) does not belong
to the quasi-concave family (6).
4 Practice
While conceptually it is convenient to think of h(t) as a continuous function, in practice we are often
faced with its discrete cousin, h(k). In this section, we first describe the typical set-up (Section 4.1).
In Section 4.2, we derive explicit expressions for the AUC and the AP under this set-up. These
expressions not only show how the AUC and the AP can be computed in practice, but they also
confirm, from a slightly different point of view, our earlier result that the AP places more emphasis
on initial true positives. To actually use the AP as a performance metric in practice, we need not
only the AP, but also its standard error. In Section 4.3, we derive the asymptotic variance for the
AP by considering the set-up given in Section 4.1.
Table 3: A diagnostic (or screening) test partitions n subjects into K groups (K distinct scores).
The broken bars (¦) illustrates the case where all those with scores ≥ xk (left) are declared to be
class-1, while all those with scores < xk (right) are declared to be class-0.
Score x1 > x2 > · · · > xk > xk+1 > · · · > xK
Partition R1 R2 · · · Rk ¦ Rk+1 · · · RK Total
Class-1 Z1 Z2 · · · Zk ¦ Zk+1 · · · ZK n1
Class-0 Z¯1 Z¯2 · · · Z¯k ¦ Z¯k+1 · · · Z¯K n0
Total S1 S2 · · · Sk ¦ Sk+1 · · · SK n
4.1 A typical set-up
In general, suppose a diagnostic (or screening) test gives K distinct scores for a total of n subjects,
with K ≤ n. If K < n, it means that some subjects’ scores are tied. The case of “no ties” simply
corresponds to the special case of K = n. With K distinct scores, the subjects are partitioned into
K groups. Within each group, some may belong to class-1 and others may belong to class-0, but
the test cannot distinguish them. We will use R1 to denote the set of all subjects receiving the top
score, R2 to denote the set of all subjects receiving the next top score, and so on for R3, ..., RK .
Furthermore, let
Sk = total number of subjects in Rk,
Zk = total number of class-1 subjects in Rk,
Z¯k = total number of class-0 subjects in Rk.
Table 3 summarizes the set-up and the notations we have just introduced.
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Figure 2: Illustration of β̂ — Eq. (14) — under four simulated scenarios, representing different
levels of prevalence, high (pi = 0.5) versus low (pi = 0.1), and different strengths of the diagnos-
tic/screening test, strong (∆ = 2) versus weak (∆ = 0.5). Dashed lines are hit curves. Solid lines
are the function, f(t) = β̂t. A total of npi scores are simulated from N(∆, 1), and the remaining
n(1− pi) scores are simulated from N(0, 1), with n = 500.
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4.2 AP versus AUC, again
Under the typical set-up (Table 3), if we threshold the scores at xk, then all those in partitions
R1, R2, ..., Rk will be declared class-1 and the rest, declared class-0. Therefore, we have
d(k) =
∑
k′≤k
Sk′ and h(k) =
∑
k′≤k
Zk′ .
As a result, Eq. (3) becomes
AUC =
1
(n1/n)(n0/n)
{
K∑
k=1
[
h(k)
n
] [
∆d(k)
n
]
− 1
2
(n1
n
)2}
=
n
n0
{
K∑
k=1
[
h(k)
n1
] [
∆d(k)
n
]}
− 1
2
(
n1
n0
)
,
where the term inside the curly brackets can be simplified further as follows:
K∑
k=1
[
h(k)
n1
] [
∆d(k)
n
]
=
[
Z1
n1
] [
S1
n
]
+
[
Z1 + Z2
n1
] [
S2
n
]
+ ...+
[
Z1 + Z2 + ...+ ZK
n1
] [
SK
n
]
=
[
S1 + S2 + ...+ SK
n
]
︸ ︷︷ ︸
w
′
1
[
Z1
n1
]
+
[
S2 + ...+ SK
n
]
︸ ︷︷ ︸
w
′
2
[
Z2
n1
]
+ ...+
[
SK
n
]
︸ ︷︷ ︸
w
′
K
[
ZK
n1
]
(15)
=
∑
k=1
w
′
k
[
Zk
n1
]
. (16)
Likewise, Eq. (5) becomes
AP =
1
(n1/n)
K∑
k=1
[
h(k)
d(k)
] [
∆h(k)
n
]
=
K∑
k=1
[
h(k)
d(k)
] [
∆h(k)
n1
]
=
[
Z1
S1
]
︸ ︷︷ ︸
w1
[
Z1
n1
]
+
[
Z1 + Z2
S1 + S2
]
︸ ︷︷ ︸
w2
[
Z2
n1
]
+ ...+
[
Z1 + Z2 + ...+ ZK
S1 + S2 + ...+ SK
]
︸ ︷︷ ︸
wK
[
ZK
n1
]
(17)
=
∑
k=1
wk
[
Zk
n1
]
. (18)
Eqs. (15) and (17) give convenient and explicit expressions for how the AUC and the AP are
calculated in practice. They also reveal that both the AUC and the AP can be expressed as
weighted averages of Z1, Z2, ..., ZK , except that they use different weights: w
′
k for the AUC and wk
for the AP.
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The difference between w
′
k and wk can most clearly be seen in the case of “no ties”, i.e., K = n.
Under such circumstances, each Rk contains just one subject, so Sk = 1 for all k, and each Zk is
either zero or one. Then, it is easy to see from Eqs. (15)-(16) and Eqs. (17)-(18) that
w
′
k =
n− d(k)
n
=
n− k + 1
n
and wk =
h(k)
k
=
(number of true positives up to k)
k
.
The main difference, therefore, is that the weights used by the AUC are independent of, whereas
the ones used by the AP are adaptive to, the test itself. Suppose Zk1 = 1 and Zk2 = 1 both belong
to class-1, where k1 < k2. When calculating the AUC for two different tests, A and B, these true
positives will each receive a fixed weight, (n− k1 − 1)/n and (n− k2 − 1)/n, respectively. For the
AP, the weights they receive will depend on the strength of the test itself; in particular, if test
A identified more class-1 subjects before k1 than did test B, the relative weight on Zk1 would be
bigger for test A than for test B. This shows, from a different point of view, that the AP places
more emphasis on early true positives than does the AUC.
4.3 Asymptotic variance of the AP
In order to use the AP as an evaluation metric, we need to obtain a formula for its variance, so
that its standard error can be computed in practice. To derive such a formula, notice that the data
in Table 3 follow the ensuing distributions:
(Z1, Z2, ..., ZK)|n1 ∼ multinomial(n1; p1, p2, ..., pK), (19)
(Z¯1, Z¯2, ..., Z¯K)|n1 ∼ multinomial(n− n1; q1, q2, ..., qK), (20)
n1 ∼ binomial(n, pi), (21)
where
pk =
∫
Rk
f1(x)dx, qk =
∫
Rk
f0(x)dx,
and fj(x) is the distribution of the scores in class-j (j = 0, 1). In addition,
(Z1, Z2, ..., ZK) ⊥⊥ (Z¯1, Z¯2, ..., Z¯K)|n1.
Therefore, the log-likelihood function (aside from a constant) is given by
`(p,q, pi) =
K∑
k=1
zk log pk +
K∑
k=1
z¯k log qk + [n1 log pi + (n− n1) log(1− pi)] , (22)
where p ≡ (p1, · · · , pK)T,q = (q1, · · · , qK)T,
K∑
k=1
pk = 1,
K∑
k=1
qk = 1,
K∑
k=1
zk = n1, and
K∑
k=1
z¯k = n− n1.
Let (p̂, q̂, pi) denote the MLEs of (p,q, pi). Then, by classical theory (e.g., Cox and Hinkley 1974),
the asymptotic variance of (p̂, q̂, pi) is simply J−1, where J is the Fisher information matrix asso-
ciated with the log-likelihood function, Eq. (22). Thus, if we can express the AP as a function of
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(p̂, q̂, pi), say AP = g(p̂, q̂, pi), then we easily can estimate its asymptotic variance using the delta
method, i.e.,
V̂ar(AP) = (∇g)T Ĵ−1 (∇g) , (23)
where Ĵ denotes the observed Fisher information matrix. Indeed, this can be done based on Eq. (17)
and the fact that
p̂k =
Zk
n1
, q̂k =
Z¯k
n− n1 , and pi =
n1
n
.
In particular, it is easy to see that
AP = g(p̂, q̂, pi) =
K∑
k=1
p̂k

pi
∑
k′≤k
p̂k′
pi
∑
k′≤k
p̂k′ + (1− pi)
∑
k′≤k
q̂k′

 . (24)
Let θ ≡ (p,q, pi) and θ̂ ≡ (p̂, q̂, pi). The calculations of
Ĵ = Ê
[
− ∂`
2
∂θ∂θT
]
and ∇g = ∂g
∂θ̂
are straight-forward; details are given in Appendix B.
5 Examples
We now provide two illustrative examples.
5.1 Mass spectrometry data for prostate cancer
Our first example concerns protein biomarkers for prostate cancer. By analyzing serum samples ob-
tained from the Virginia Prostate Center Tissue and Body Fluid Bank, Adam et al. (2002) identified
779 potential biomarkers using a technology called “surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry” (Issaq et al. 2002). Wang and Chang (2011) used this data set
to illustrate the partial AUC (see Section 1). We focused on the n1 = 83 patients with late-stage
prostate cancer (class 1) and the n0 = 82 normal individuals (class 0) in the data set, although the
original data set also included patients with early-stage cancer and patients with benign prostate
hyperplasia.
Figure 3 shows the AP versus the AUC for the top 15 biomarkers as ranked by the AP. We can
see clearly that, while some biomarkers (e.g., 3896.614) are ranked similarly on both scales, others
(e.g., 8355.562, 8141.232, 5074.164, 6949.220, 7819.751) are ranked very differently. For example,
according to both the AP and the AUC, 3896.641 is a top biomarker. On the other hand, according
to the AUC, there is little difference between 8355.562 and 7819.751 whereas, according to the AP,
8355.562 is more powerful.
Figure 4 compares the ROC curves of two selected pairs of biomarkers: A (8355.562 and
7819.751), which scored quite similarly on the AUC-scale but very differently on the AP-scale; and
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Figure 3: Prostate cancer example (Section 5.1). Top 15 biomarkers according to the AP. Biomark-
ers are not labelled unless they are explicitly mentioned in the text.
B (8141.232 and 5074.164), which scored more or less similarly on the AP-scale but very differently
on the AUC-scale. We clearly can see from this figure that the two biomarkers in pair A have
qualitatively different ROC curves, yet their AUC-values are very similar. This is an unmistakable
case of the momentum-stamina tradeoff that we discussed in Section 3.3 — even though the areas
under their ROC curves are obviously very similar, the biomarker 8355.562 also can be recognized
from its ROC curve to have a much larger momentum, which is why it scored much higher on the
AP-scale, since the AP awards extra points to momentum (Section 3.4). For the two biomarkers
in pair B, one immediately can discern from Figure 4 that 5074.164 has a much larger area under
its ROC curve (i.e., larger AUC), yet their AP-values are more or less the same — in fact, the AP
of 8141.232 is slightly higher than that of 5074.164. Again, this is due to the biomarker 8141.232
having a slightly larger momentum, a fact also noticeable from the figure.
Table 4 contains various standard error estimates for the top 15 biomarkers displayed in Fig-
ure 3. Here, we can see that the asymptotic estimates (Section 4.3) do, in fact, agree closely with
standard bootstrap estimates (Efron and Tibshirani 1996). To obtain the parametric bootstrap
estimates, we first estimated the multinomial models (19)–(21), and then used the estimated pa-
rameters (p̂k, q̂k, pi) to generate B = 5, 000 multinomial samples. For the nonparametric bootstrap,
we simply drew B = 5, 000 bootstrap samples, each by resampling from the original data set with
replacement.
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Table 4: Prostate cancer example (Section 5.1). The top 15 biomarkers according to the AP.
“P-Bootstrap” = parametric bootstrap. “NP-Bootstrap” = nonparametric bootstrap.
Standard Error of AP
Biomarker AP Asymptotic P-Bootstrap NP-Bootstrap
1 3896.641 0.878 0.0345 0.0344 0.0344
2 8355.562 0.856 0.0336 0.0339 0.0340
3 8141.232 0.850 0.0319 0.0324 0.0321
4 8295.641 0.833 0.0328 0.0327 0.0327
5 5074.164 0.833 0.0403 0.0405 0.0403
6 4071.184 0.831 0.0368 0.0364 0.0366
7 6949.220 0.824 0.0414 0.0415 0.0413
8 9149.121 0.822 0.0378 0.0380 0.0378
9 5914.398 0.811 0.0355 0.0345 0.0355
10 28142.463 0.803 0.0395 0.0394 0.0402
11 7819.751 0.802 0.0424 0.0427 0.0423
12 7195.206 0.796 0.0317 0.0316 0.0318
13 16264.029 0.790 0.0320 0.0321 0.0319
14 7775.625 0.786 0.0441 0.0451 0.0442
15 8544.842 0.776 0.0388 0.0389 0.0390
Table 5: Breast cancer example (Section 5.2). Film versus digital mammography. “P-Bootstrap”
= parametric bootstrap. “NP-Bootstrap” = nonparametric bootstrap.
Mammography Standard Error of AP
Type AUC AP Asymptotic P-Bootstrap NP-Bootstrap
Digital 0.753 0.144 0.0197 0.0197 0.0194
Film 0.735 0.166 0.0219 0.0216 0.0215
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(b) Pair B: (8141.232, 5074.164).
Figure 4: Prostate cancer example (Section 5.1). Comparison of ROC curves for biomarkers that
are rankly differently by the AP and by the AUC. Pair A (8355.562, 7819.751) scored similarly on
the AUC-scale but very differently on the AP-scale. Pair B (8141.232, 5074.164) scored more or
less similarly on the AP-scale but very differently on the AUC-scale.
5.2 Mammography data for breast cancer
Our second example concerns the Digital Mammographic Imaging Screening Trial (DMIST; Pisano
et al. 2005), comparing digital versus film mammography for breast cancer screening. Over 42,000
women were enrolled in the trial and underwent both digital and film mammography. Using a
seven-point malignancy scale, each pair of mammograms were rated separately by two independent
radiologists. At 15-month follow-up, a total of 335 breast cancers were confirmed in the final cohort,
and the question was: which type of mammography better predicted these cases of cancer?
We analyzed the data from Pisano et al. (2005, Table 3). The AUC and the AP for the two
technologies are given in Table 5, together with various standard error estimates of the AP. As in
the previous example (Table 4), the different standard error estimates are in good agreement with
each other.
Overall, digital mammography fared slightly better than film mammography on the AUC-scale,
but the AP favored film mammography slightly over digital mammography. Thus, depending on
the performance measure, we could arrive at different conclusions about which technology was more
effective for detecting breast cancer. The difference in AP (or in AUC) between the two types of
mammography was relatively small. We could not test formally whether these small differences
18
were statistically significant because the malignancy scores based on digital mammograms and
those based on film mammograms were not independent, as the mammograms were taken on the
same group of patients and rated by the same group of radiologists. While
Var(APfilm −APdigital) = Var(APfilm) + Var(APdigital)− 2Cov(APfilm,APdigital),
estimating the covariance term, even by the bootstrap, would require us to have information about
which pair of scores — one from digital and another from film mammography — was for the same
patient. We didn’t have such information but, given the context, it was safe to conjecture that the
covariance term most likely would have been positive. Hence, by using the standard error estimates
in Table 5 and letting ρ be the (unknown) correlation coefficient between APfilm and APdigital, we
can estimate the standard error of the difference, APfilm −APdigital, as a function of ρ:
se(APfilm −APdigital) ≈
√
(0.02)2 + (0.02)2 − 2ρ(0.02)(0.02) ≈

0.020, if ρ = 0.5;
0.015, if ρ = 0.7;
0.009, if ρ = 0.9.
These simple calculations suggest that a difference of about 0.166− 0.144 = 0.022 on the AP-scale
can still be statistically significant if the correlation between digital and film mammography is
relatively high, which most likely is the case in reality.
The DMIST publication (Pisano et al. 2005) used the AUC as the main performance measure.
Despite their enthusiasm about the effectiveness of digital mammography, the U.S. Preventive Ser-
vices Task Force recently concluded that “[e]vidence is lacking for benefits of digital mammography
and MRI of the breast as substitutes for film mammography” (U.S. Preventive Services Task Force
2009). The assessment provided by the AP seems to be in line with the latter conclusion.
6 Discussions
We have shown in Section 3 that, relative to the AUC, the AP places additional emphasis on the
initial true positive rate — or simply momentum, as we have defined it in Section 3.2. In practice,
when do we care more about the momentum of a test? We think the momentum is especially
important when pi is relatively small, that is, when the prevalence is low. This is because, when the
prevalence is low, we naturally would like to avoid raising too many red flags, but for the precious
few flags that we do raise (i.e., the few top-ranked cases), we’d like to have as many true positives
as possible.
Most medical screening tests do indeed operate under such circumstances, i.e., low prevalence,
because the purposes of these tests are to identify diseases in their early stages, when no symptoms
are present, so as to facilitate early intervention with the hope to improve outcomes (Thorner and
Remein 1961). Therefore, they target a general, asymptomatic population (Raffle and Gray 2007),
among which the prevalence is typically very low. By contrast, most diagnostic tests are aimed at
patients who already display some kind of symptoms, so they typically are meant for situations
where the prevalence is considerably higher. For assessing screening (as opposed to diagnostic)
tests, therefore, a performance metric that emphasizes the test’s momentum, such as the AP, may
be more attractive than a metric that treats momentum and stamina as being equally important,
such as the AUC. In the breast cancer example (Section 5.2), the disease prevalence was 0.0078 at
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Table 6: Prostate cancer example (Section 5.1). A simple thought experiment showing changes in
the AUC and in the AP as a result of artificially inflating the number of control subjects (n0).
AUC AP
Biomarkers n0 × 1 n0 × 10 n0 × 100 n0 × 1 n0 × 10 n0 × 100
A 8355.562 0.849 0.783 0.783 0.856 0.606 0.571
7819.751 0.850 0.857 0.857 0.802 0.370 0.062
B 8141.232 0.810 0.773 0.773 0.850 0.572 0.468
5074.164 0.886 0.869 0.869 0.833 0.306 0.043
15 months post-screening. In practice, radiologists do consider these very low prevalence numbers
when assigning malignancy scores so as to avoid too many false positives (Rosenberg et al. 2006).
In other words, precision is of particular interest for screening, and clinicians may very well prefer
a screening test that is favored by the AP to one that is favored by the AUC.
Sometimes, we may have conducted a case-control study (for which pi ≈ 50% by design),
but would like to use the case-control data to identify biomarkers for the purpose of performing
future screening tests (for which pi is expected to be much smaller). In such applications, it also
may be much better to use the AP rather than the AUC to assess the potential biomarkers. In
the prostate cancer example (Section 5.1), biomarkers were evaluated under a case-control design
(n1 = 83 ≈ 82 = n0) for their potential as screening tools for prostate cancer. To see how
their relative evaluations would change if the prevalence were much lower, we conducted a simple
thought experiment on the two pairs of biomarkers shown in Figure 4, and examined what would
happen if we artificially inflated the number of control subjects by creating copies of each existing
control subject in the data set (Table 6). For pair A (8355.562, 7819.751), we already have seen
in Section 5.1 that the two scored similarly on the AUC-scale despite having very different ROC
curves — a clear case of momentum-stamina tradeoff, and that the marker 8355.562 scored higher
on the AP-scale due to its large momentum. Here, we can see that the difference between the
two markers becomes even more dramatic on the AP-scale when the prevalence is reduced. For
pair B (8141.232, 5074.164), we see that, even though the marker 5074.164 scored higher on the
AUC-scale, based on the case-control data, the AP is more or less indifferent between the two, but,
when the prevalence is reduced, the AP can actually start to favor the other marker 8141.232 by a
substantial margin.
Finally, we think the AP is useful not only for medical screening tests, but also for the risk
prediction of low probability events in general. Often, models are constructed and covariates are
selected in order to predict some future event in a specific population, e.g., the risk of having
a cardiovascular event in the next 10 years, or the risk of having a secondary neoplasm in the
next 10 years for childhood cancer survivors, and so on. One of the main objectives is to identify
patients who have a high risk of developing these conditions. Since many of these events have low
probabilities, meaning that the incidence rate is low, the AP may be a better performance measure
than the AUC for reasons similar to those discussed above. Currently, however, prediction models
and competing risk factors are almost exclusively assessed by ROC curves and more specifically,
by the AUC (Buijsse et al. 2011).
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A Proof of Proposition 1
(a) This follows from the very definition of the hit curve. Initially (t = 0), no subject is declared
positive (belonging to class-1), so h(0) = 0. In the end (t = 1), every subject is declared
positive including all true positives, so h(1) = pi.
(b) This follows from the fact that, going from t to t+∆t, the worst case is that no additional true
positives are identified, and the best case is that every subject identified is a true positive.
That is,
0 ≤ h(t+ ∆t)− h(t) ≤ ∆t ⇒ 0 ≤ h(t+ ∆t)− h(t)
∆t
≤ 1
for all ∆t > 0. Taking the limit on both sides gives
0 ≤ lim
∆t→0
h(t+ ∆t)− h(t)
∆t
≤ 1,
or 0 ≤ h′(t) ≤ 1.
(c) Integration by parts implies∫
h(t)dh(t) =
[
h2(t)
]1
0
−
∫
h(t)dh(t).
Solving for
∫
h(t)dh(t) gives ∫
h(t)dh(t) =
h2(1)− h2(0)
2
=
pi2
2
,
by Proposition 1(a).
B Asymptotic variance of the AP: Some details
Due to the multinomial constraints, p1 + ... + pK = 1 and q1 + ... + qK = 1, in practice we work
with (K−1)-dimensional vectors, p and q, rather than K-dimensional vectors. By direct algebraic
calculations, we can obtain that
Ĵ =
 P − −− Q −
− − a
 ,
where P, Q are (K − 1)× (K − 1) matrices with
Pkk =
zk
p̂2k
+
zK
p̂2K
for k = 1, ...,K − 1, Pkk′ = zK
p̂2K
for all k 6= k′,
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Qkk =
z¯k
q̂2k
+
z¯K
q̂2K
for k = 1, ...,K − 1, Qkk′ = z¯K
q̂2K
for all k 6= k′,
and
a =
n1
pi2
+
n0
(1− pi)2 .
Now, let
Pk ≡
∑
k′≤k
p̂k′ , Qk ≡
∑
k′≤k
q̂k′ , and Ck ≡ piPk + (1− pi)Qk.
Again, by direct algebraic calculations, we can obtain that
∇g =
 ∇p∇q
∇pi

where ∇p, ∇q are (K − 1)-dimensional vectors with
∇p(k) ≡ ∂g
∂p̂k
=
piPk
Ck
+
K−1∑
k′=k
p̂k′
[
pi(1− pi)Qk′
C2k′
]
− pi,
∇q(k) ≡ ∂g
∂q̂k
=
K−1∑
k′=k
p̂k′
[−pi(1− pi)Pk′
C2k′
]
,
for k = 1, ...,K − 1, and
∇pi ≡ ∂g
∂pi
=
K∑
k=1
p̂k
[
PkQk
C2k
]
.
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